Patents by Inventor Argyrios G. Arvanitis

Argyrios G. Arvanitis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
    Patent number: 8486902
    Abstract: The present invention provides hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: July 16, 2013
    Assignee: Incyte Corporation
    Inventors: James D. Rodgers, Adam Shilling, Argyrios G. Arvanitis, Stacey Shepard, Laurine G. Galya, Mei Li, Frank M. Nedza
  • Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
    Patent number: 8415362
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines of Formula I: that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: April 9, 2013
    Assignee: Incyte Corporation
    Inventors: James D. Rodgers, Stacey Shepard, Thomas P. Maduskuie, Haisheng Wang, Nikoo Falahatpisheh, Maria Rafalski, Argyrios G. Arvanitis, Louis Storace, Ravi Kumar Jalluri
  • Cyclohexyl Azetidine Derivatives as JAK Inhibitors
    Publication number: 20130045963
    Abstract: The present invention provides cyclohexyl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: August 17, 2012
    Publication date: February 21, 2013
    Applicant: INCYTE CORPORATION
    Inventors: James D. Rodgers, Argyrios G. Arvanitis
  • AZEPINE INHIBITORS OF JANUS KINASES
    Publication number: 20120329782
    Abstract: The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: May 23, 2012
    Publication date: December 27, 2012
    Applicant: INCYTE CORPORATION
    Inventors: Argyrios G. Arvanitis, James D. Rodgers, Andrew P. Combs, Richard B. Sparks, Darius J. Robinson, Jordan S. Fridman, Krishna Vaddi
  • HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
    Publication number: 20110223210
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: March 30, 2011
    Publication date: September 15, 2011
    Inventors: James D. Rodgers, Stacey Shepard, Thomas P. Maduskuie, JR., Haisheng Wang, Nikoo Falahatpisheh, Maria Rafalski, Argyrios G. Arvanitis, Louis Storace, Ravikumar Jalluri, Jordan S. Fridman, Krishna Vaddi
  • HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
    Publication number: 20110224157
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: March 30, 2011
    Publication date: September 15, 2011
    Inventors: James D. Rodgers, Stacey Shepard, Thomas P. Maduskuie, JR., Haisheng Wang, Nikoo Falahatpisheh, Maria Rafalski, Argyrios G. Arvanitis, Louis Storace, Ravi Kumar Jalluri, Jordan S. Fridman, Krishna Vaddi
  • HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d] PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
    Publication number: 20110086810
    Abstract: The present invention provides hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.
    Type: Application
    Filed: October 8, 2010
    Publication date: April 14, 2011
    Applicant: INCYTE CORPORATION
    Inventors: James D. RODGERS, Adam SHILLING, Argyrios G. ARVANITIS, Stacey SHEPARD, Laurine G. GALYA, Mei LI, Frank M. NEDZA
  • METABOLITES OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
    Publication number: 20110082159
    Abstract: The present invention provides active metabolites of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: October 7, 2010
    Publication date: April 7, 2011
    Applicant: INCYTE CORPORATION
    Inventors: James D. RODGERS, Argyrios G. ARVANITIS, Jack Guoen SHI, Stacey SHEPARD
  • N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
    Publication number: 20100298334
    Abstract: The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I: which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
    Type: Application
    Filed: May 21, 2010
    Publication date: November 25, 2010
    Inventors: James D. Rodgers, Stacey Shepard, Argyrios G. Arvanitis, Haisheng Wang, Louis Storace, Beverly Folmer, Lixin Shao, Wenyu Zhu, Joseph Glenn
  • HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
    Publication number: 20100022522
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: August 27, 2009
    Publication date: January 28, 2010
    Inventors: James D. Rodgers, Stacey Shepard, Thomas P. Maduskuie, JR., Haisheng Wang, Nikoo Falahatpisheh, Maria Rafalski, Argyrios G. Arvanitis, Louis Storace, Ravikumar Jalluri, Jordan S. Fridman, Krishna Vaddi
  • TETRACYCLIC INHIBITORS OF JANUS KINASES
    Publication number: 20090215766
    Abstract: The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.
    Type: Application
    Filed: August 6, 2008
    Publication date: August 27, 2009
    Inventors: James D. Rodgers, Darius J. Robinson, Argyrios G. Arvanitis, Thomas P. Maduskuie, JR., Stacey Shepard, Louis Storace, Haisheng Wang, Maria Rafalski, Ravi Kumar Jalluri, Andrew P. Combs, Matthew L. Crawley
  • AZEPINE INHIBITORS OF JANUS KINASES
    Publication number: 20090197869
    Abstract: The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: April 3, 2009
    Publication date: August 6, 2009
    Inventors: Argyrios G. Arvanitis, James D. Rodgers, Andrew P. Combs, Richard B. Sparks, Darius J. Robinson
  • HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
    Publication number: 20090181959
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: June 12, 2008
    Publication date: July 16, 2009
    Applicant: INCYTE CORPORATION
    Inventors: James D. Rodgers, Stacey Shepard, Thomas P. Maduskuie, JR., Haisheng Wang, Nikoo Falahatpisheh, Maria Rafalski, Argyrios G. Arvanitis, Louis Storace, Ravi Kumar Jalluri, Jordan S. Fridman, Krishna Vaddi
  • METABOLITES OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
    Publication number: 20080312258
    Abstract: The present invention provides active metablites of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: June 12, 2008
    Publication date: December 18, 2008
    Applicant: INCYTE CORPORATION
    Inventors: James D. Rodgers, Argyrios G. Arvanitis, Jack Guoen Shi
  • SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS
    Publication number: 20080188500
    Abstract: The present invention provides substituted tricyclic heteroaryl compounds, including, for example, pyridoindoles, pyrimidinoindoles and triazinoindoles that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases such as immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: December 20, 2007
    Publication date: August 7, 2008
    Inventors: Argyrios G. Arvanitis, James D. Rodgers, Louis Storace, Beverly Folmer
  • Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
    Patent number: 7319100
    Abstract: Compounds provided herein are novel substituted pyrazinones, pyridines and pyrimidines of Formula (I) and (II): Such compounds are particularly useful as CRF receptor ligands, and hence, in the treatment of various neurologically-related disorders such as affective disorder, anxiety and depression.
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: January 15, 2008
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Argyrios G. Arvanitis, Paul J. Gilligan, Richard A. Hartz
  • Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
    Patent number: 7205306
    Abstract: Compounds provided herein are novel substituted pyrazinones, pyridines and pyrimidines of Formula (I) and (II): Such compounds are particularly useful as CRF receptor ligands, and hence, in the treatment of various neurologically-related disorders such as affective disorder, anxiety and depression.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: April 17, 2007
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Argyrios G Arvanitis, Paul J Gilligan, Richard A Hartz
  • Pyrimidine derivatives as corticotropin releasing factor inhibitors
    Patent number: 7112585
    Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: September 26, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Argyrios G. Arvanitis
  • Pyridinyl derivatives for the treatment of depression
    Patent number: 7030145
    Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: April 18, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Argyrios G. Arvanitis
  • Pyrimidine derivatives as corticotropin releasing factor inhibitors
    Publication number: 20040229891
    Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) 1
    Type: Application
    Filed: March 12, 2004
    Publication date: November 18, 2004
    Inventors: Richard A. Hartz, Argyrios G. Arvanitis